Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus CEFTRIAXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus CEFTRIAXONE.
CEFACLOR vs CEFTRIAXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
250-500 mg orally every 8 hours
1-2 g IV/IM every 24 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCeftriaxone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftriaxone."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateCeftriaxone + Picosulfuric acid
Terminal half-life: 5.8-8.7 hours in adults; prolonged to 12-24 hours in neonates and 30-90 hours in severe renal impairment.
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Renal (33-67% unchanged) and biliary (up to 40%) with fecal elimination. In neonates, renal excretion is lower (~20%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone."